147 related articles for article (PubMed ID: 23733230)
21. [Molecular analysis of transformation into blast crisis in chronic myelogenous leukemia].
Okabe M
Hokkaido Igaku Zasshi; 1993 Mar; 68(2):237-50. PubMed ID: 8509066
[TBL] [Abstract][Full Text] [Related]
22. Chronic myelogenous leukemia: mechanisms underlying disease progression.
Shet AS; Jahagirdar BN; Verfaillie CM
Leukemia; 2002 Aug; 16(8):1402-11. PubMed ID: 12145676
[TBL] [Abstract][Full Text] [Related]
23. [BMMSC from blastic phase CML down-regulate leukemia cell apoptosis].
Wang Y; Han YX; Niu ZY; Wang XZ; Hua H; Shang YT; Wang FX; Zhang XJ; Luo JM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1402-7. PubMed ID: 25338597
[TBL] [Abstract][Full Text] [Related]
24. [Influence of IFN-alpha and IFN-alpha combined with GM-CSF on expression of the genes related to cell apoptosis of MNCs from bone marrow in CML patients].
Tang LJ; Chen HC; Peng XH
Hunan Yi Ke Da Xue Xue Bao; 2000 Dec; 25(6):570-2. PubMed ID: 12516408
[TBL] [Abstract][Full Text] [Related]
25. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
26. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance.
Inokuchi K; Yamaguchi H; Tarusawa M; Futaki M; Hanawa H; Tanosaki S; Dan K
Leukemia; 2002 Feb; 16(2):170-7. PubMed ID: 11840282
[TBL] [Abstract][Full Text] [Related]
27. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
28. [Expression of bcl-2 gene in the evolution of chronic myelogenous leukemia to blast crisis and its implication].
Sui X; Su L; Chu J
Zhonghua Xue Ye Xue Za Zhi; 1999 Jan; 20(1):27-9. PubMed ID: 11498840
[TBL] [Abstract][Full Text] [Related]
29. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
30. Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors.
Kuribara R; Honda H; Matsui H; Shinjyo T; Inukai T; Sugita K; Nakazawa S; Hirai H; Ozawa K; Inaba T
Mol Cell Biol; 2004 Jul; 24(14):6172-83. PubMed ID: 15226421
[TBL] [Abstract][Full Text] [Related]
31. [Study of apoptosis induced by indomethacin in chronic myeloid leukemia].
Tu C; Zhang G; Lu H
Zhonghua Xue Ye Xue Za Zhi; 1999 Jul; 20(7):362-5. PubMed ID: 11721434
[TBL] [Abstract][Full Text] [Related]
32. Absence of bcr/abl gene in single hemopoietic progenitors in some patients with chronic myelogenous leukemia.
Misawa M; Maeda H; Hara H; Yamamoto Y; Furuyama J
Stem Cells; 1993 Nov; 11(6):536-42. PubMed ID: 7509222
[TBL] [Abstract][Full Text] [Related]
33. Philadelphia-chromosome-positive T-lymphoblastic leukemia: acute leukemia or chronic myelogenous leukemia blastic crisis.
Raanani P; Trakhtenbrot L; Rechavi G; Rosenthal E; Avigdor A; Brok-Simoni F; Leiba M; Amariglio N; Nagler A; Ben-Bassat I
Acta Haematol; 2005; 113(3):181-9. PubMed ID: 15870488
[TBL] [Abstract][Full Text] [Related]
34. Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model.
Park J; Kim KI; Koh Y; Won NH; Oh JM; Lee DS; Kim BK; Ahn KS; Yoon SS
Exp Hematol; 2010 Sep; 38(9):773-81. PubMed ID: 20438801
[TBL] [Abstract][Full Text] [Related]
35. Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells.
Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
Exp Cell Res; 2009 Jul; 315(11):1809-18. PubMed ID: 19268463
[TBL] [Abstract][Full Text] [Related]
36. bcr/abl mRNA in leukemic blasts of an unusual patient with acute lymphoblastic leukemia followed after 5-year remission by chronic myelogenous leukemia in blast crisis.
Fujie H; Tsuchiya S; Morita S; Itano M; Yambe T; Ohasi Y; Minegishi N; Minegishi M; Satou T; Konno T
Leukemia; 1994 Sep; 8(9):1592-5. PubMed ID: 8090037
[TBL] [Abstract][Full Text] [Related]
37. c-abl function in normal and chronic myelogenous leukemia hematopoiesis: in vitro studies with antisense oligomers.
Rosti V; Bergamaschi G; Ponchio L; Cazzola M
Leukemia; 1992 Jan; 6(1):1-7. PubMed ID: 1736009
[TBL] [Abstract][Full Text] [Related]
38. Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: chronic myelogenous leukemia presenting in lymphoid blast vs Ph+ acute lymphoblastic leukemia.
Anastasi J; Feng J; Dickstein JI; Le Beau MM; Rubin CM; Larson RA; Rowley JD; Vardiman JW
Leukemia; 1996 May; 10(5):795-802. PubMed ID: 8656674
[TBL] [Abstract][Full Text] [Related]
39. High IL-7 levels in the bone marrow microenvironment mediate imatinib resistance and predict disease progression in chronic myeloid leukemia.
Zhang X; Tu H; Yang Y; Wan Q; Fang L; Wu Q; Li J
Int J Hematol; 2016 Sep; 104(3):358-67. PubMed ID: 27272942
[TBL] [Abstract][Full Text] [Related]
40. Phenotypic and gene expression diversity of malignant cells in human blast crisis chronic myeloid leukemia.
Simanovsky M; Berlinsky S; Sinai P; Leiba M; Nagler A; Galski H
Differentiation; 2008 Oct; 76(8):908-22. PubMed ID: 18452548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
